Daratumumab for Myalgic Encephalomyelitis (ME/CFS)

We are studying whether the drug daratumumab can help reduce symptoms in people with moderate to severe ME/CFS. The trial will also assess its safety compared to a placebo.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Darzalex
Darzalex is a medicine used to treat multiple myeloma, a type of blood cancer.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Daratumumab
Daratumumab is a substance that helps treat multiple myeloma, a blood cancer, by directing the immune system to attack the cancerous plasma cells.
Hyaluronidase
Hyaluronidase is a substance that breaks down hyaluronic acid to help injected fluids spread and to treat complications from hyaluronic fillers.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Hyaluronidase

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Helse Bergen HF
Cancer Clinic
Bergen, Norway
Oslo University Hospital HF
Dept. of Oncology
Oslo, Norway
Sponsor: Helse Bergen HF
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.